Biocept Inc (BIOC)-医療機器分野:企業M&A・提携分析

◆英語タイトル:Biocept Inc (BIOC) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA8011476
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月22日
◆ページ数:86
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Biocept Inc (Biocept) is a developer of diagnostic solutions. The company provides biopharmaceutical and clinical research, and molecular oncology laboratory services. It provides tests for various solid tumor cancers. Biocept offers related instrumentation, OncoCEE technology, and analytical capabilities for rare event detection and genetic characterization. The company’s OncoCEE platform modifies rare cell capture and analyses methods. It offers patented methodology to isolate rare cells including circulating tumor cells, and cell-free circulating tumor DNA from the blood. The company also develops methodology to isolate cancer material including circulating tumor cells, and cell-free circulating tumor DNA. It serves medical and surgical oncologists, pathologists, hospitals, cancer centers, universities, and pharmaceutical and clinical researchers. Biocept is headquartered in San Diego, California, the US.

Biocept Inc (BIOC) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Biocept Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Biocept Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Biocept Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Biocept Inc, Medical Equipment, Deals By Market, 2011 to YTD 2017 9
Biocept Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Biocept Inc, Medical Equipment, Deal Details 12
Venture Financing 12
Biocept Raises Funds In Growth Equity Financing Round 12
Partnerships 13
Biocept Enters into Marketing Agreement with Miraca Life Sciences 13
Biocept Enters into Agreement with University of Texas Southwestern Medical Center 14
Addario Lung Cancer Medical Institute and Biocept Enter into Partnership 15
Biocept Enters into Agreement with OHSU Knight Cancer Institute 16
Biocept Enters into Agreement with Catalyst Pharma 17
Biocept Enters into Agreement with Teneovita Medical Innovations 18
Biocept Forms Partnership with MedStar Georgetown University Hospital 19
Biocept to Form Partnership with Quest Diagnostics Mexico 20
Biocept Enters into Agreement 21
Biocept Enters into Distribution Agreement with Progenetics 22
Biocept Enters into Co-Development Agreement with Baylor College of Medicine 23
Biocept Enters into Partnership with Life Technologies 24
Biocept Enters Into Co-Marketing Agreement With Clarient 25
Equity Offering 26
Biocept Prices Public Offering of Shares for USD3.3 Million 26
Biocept Prices USD3.3 Million in Public Offering of Shares 28
Biocept Plans to Raise Funds through Private Placement of Shares 29
Biocept to Raise USD2.2 Million in Private Placement of Shares and Warrants 30
Biocept Prices Private Placement of Shares and Warrants for USD9.3 Million 31
Biocept Raises USD10 Million in Public Offering of Shares and Warrants 32
Biocept Prices Public Offering of Shares and Warrants for USD5 Million 33
Biocept to Raise USD15 Million in Public Offering of Shares 34
Biocept Raises USD10 Million in Public Offering of Shares and Warrants 35
Biocept Completes IPO For US$19 Million 37
Biocept Raises USD2 Million in Private Placement of Series A Preferred Stock 38
Biocept Inc – Key Competitors 39
Biocept Inc – Key Employees 40
Biocept Inc – Locations And Subsidiaries 41
Head Office 41
Recent Developments 42
Financial Announcements 42
Nov 09, 2017: Biocept Reports Third Quarter 2017 Financial Results 42
Aug 10, 2017: Biocept Reports Second Quarter 2017 Financial Results 45
May 11, 2017: Biocept Reports First Quarter 2017 Financial Results 48
Mar 07, 2017: Biocept Reports Fourth Quarter and Full Year 2016 Financial Results 50
Nov 09, 2016: Biocept Reports 2016 Third Quarter Financial Results 52
Aug 02, 2016: Biocept Reports 2016 Second Quarter Financial Results 54
May 12, 2016: Biocept Reports 2016 First Quarter Financial Results 56
Mar 09, 2016: Biocept Reports 2015 Fourth Quarter and Full Year Financial Results 57
Corporate Communications 59
Oct 11, 2017: Renowned Lung Cancer Expert Fred R. Hirsch, M.D., Ph.D. Joins Biocept’s Clinical Advisory Board 59
Feb 15, 2017: Biocept Appoints Michael Terry Senior Vice President Commercial Operations 60
Oct 27, 2016: Biocept Appoints David Moskowitz Vice President, Strategy & Corporate Communications 61
Jul 27, 2016: Biocept Appoints Timothy C. Kennedy as Chief Financial Officer and Senior Vice President of Operations 62
Mar 23, 2016: Biocept’s Mark Foletta Honored with CFO Lifetime Achievement Award 64
Product News 65
Dec 05, 2017: First U.S. Patent Issued for Biocept’s Target Selector Oncogene Mutation Enrichment and Detection Liquid Biopsy ctDNA Platform 65
Sep 23, 2016: Biocept’s Proprietary Liquid Biopsy Platform to be Featured at Two Upcoming Molecular Diagnostics Conferences 66
Sep 01, 2016: Biocept Expands Chinese Patent Protection Covering Key Technologies for Circulating Tumor Cell Capture and Analysis Used in Liquid Biopsy Tests 67
Aug 18, 2016: Biocept to Present at Next Generation Dx Summit 68
Jul 05, 2016: Biocept Granted Japanese Patent Covering Microchannel and Antibody Capture 69
May 25, 2016: High Sensitivity of Biocept’s Target Selector Blood-Based Liquid Biopsy Tests Featured in Two Abstracts at ASCO 70
May 12, 2016: Biocept Expands Intellectual Property Portfolio with 12th Granted Patent on its Key Liquid Biopsy Technology 71
Apr 27, 2016: Biocept Collaborates with MedStar Georgetown University Hospital for Liquid Biopsy Study 72
Mar 03, 2016: Biocept to Present at Molecular Medicine Tri-Con 2016 73
02/26/2016: Data Demonstrating Extremely High Sensitivity of Biocept’s Blood-Based Liquid Biopsy in Detecting Lung Cancer Mutations Presented at UCSD Moores Cancer Center Translational Oncology Symposium 74
Other Significant Developments 75
Dec 18, 2017: Biocept Signs In-Network Provider Agreement with Wellmark Blue Cross Blue Shield Expanding Coverage for its Target Selector Platform in Iowa and South Dakota 75
Oct 18, 2017: Biocept Launches Pathology Partnership Initiative Expanding Access of Proprietary Liquid Biopsy Testing to Community Pathologists and Hospitals 76
Aug 14, 2017: Biocept Enters Into Exclusive Distribution Agreement with Global Laboratory Product Supplier VWR 77
Aug 07, 2017: Biocept Executes Preferred Provider Agreement with Scripps Health Plan Expanding Patient Coverage for its Liquid Biopsy Platform 78
Jan 10, 2017: Biocept Secures In-Network Provider Agreement with Blue Cross Blue Shield of Texas 79
Sep 09, 2016: Biocept to Collaborate with Renowned Clinical Investigator Dr. Shilpa Gupta to Study the Utility of Liquid Biopsy Testing in Bladder and Prostate Cancers 80
Aug 11, 2016: Biocept Expands Distribution of Liquid Biopsy Tests to the Philippines 81
May 23, 2016: Biocept Announces Master Services Agreement with Pharma Company to Develop Liquid Biopsy Tests 82
Mar 10, 2016: Progenetics to Distribute Biocept’s Liquid Biopsy Assays in Israel 83
Feb 29, 2016: Biocept Secures Agreement with Preferred Provider Organization Prime Health Services 84
Jan 12, 2016: Biocept Announces In-Network Agreement with Blue Cross Blue Shield of Illinois 85
Appendix 86
Methodology 86
About GlobalData 86
Contact Us 86
Disclaimer 86

List of Tables
Biocept Inc, Medical Equipment, Key Facts, 2016 2
Biocept Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
Biocept Inc, Medical Equipment, Deals By Year, 2011 to YTD 2017 6
Biocept Inc, Medical Equipment Deals By Type, 2011 to YTD 2017 7
Biocept Inc, Medical Equipment, Deals By Region, 2011 to YTD 2017 8
Biocept Inc, Deals By Market, 2011 to YTD 2017 9
Biocept Inc, Medical Equipment, Deals Summary, 2011 to YTD 2017 10
Biocept Raises Funds In Growth Equity Financing Round 12
Biocept Enters into Marketing Agreement with Miraca Life Sciences 13
Biocept Enters into Agreement with University of Texas Southwestern Medical Center 14
Addario Lung Cancer Medical Institute and Biocept Enter into Partnership 15
Biocept Enters into Agreement with OHSU Knight Cancer Institute 16
Biocept Enters into Agreement with Catalyst Pharma 17
Biocept Enters into Agreement with Teneovita Medical Innovations 18
Biocept Forms Partnership with MedStar Georgetown University Hospital 19
Biocept to Form Partnership with Quest Diagnostics Mexico 20
Biocept Enters into Agreement 21
Biocept Enters into Distribution Agreement with Progenetics 22
Biocept Enters into Co-Development Agreement with Baylor College of Medicine 23
Biocept Enters into Partnership with Life Technologies 24
Biocept Enters Into Co-Marketing Agreement With Clarient 25
Biocept Prices Public Offering of Shares for USD3.3 Million 26
Biocept Prices USD3.3 Million in Public Offering of Shares 28
Biocept Plans to Raise Funds through Private Placement of Shares 29
Biocept to Raise USD2.2 Million in Private Placement of Shares and Warrants 30
Biocept Prices Private Placement of Shares and Warrants for USD9.3 Million 31
Biocept Raises USD10 Million in Public Offering of Shares and Warrants 32
Biocept Prices Public Offering of Shares and Warrants for USD5 Million 33
Biocept to Raise USD15 Million in Public Offering of Shares 34
Biocept Raises USD10 Million in Public Offering of Shares and Warrants 35
Biocept Completes IPO For US$19 Million 37
Biocept Raises USD2 Million in Private Placement of Series A Preferred Stock 38
Biocept Inc, Key Competitors 39
Biocept Inc, Key Employees 40

★海外企業調査レポート[Biocept Inc (BIOC)-医療機器分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Moneygram International, Inc.:企業のM&A・事業提携・投資動向
    Moneygram International, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Moneygram International, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and …
  • Rockefeller University-製薬・医療分野:企業M&A・提携分析
    Summary Rockefeller University (Rockefeller) is a biomedical research university that provides graduate and postdoctoral educational programs. The university offers various educational courses in the fields of biomedical sciences, chemistry, bioinformatics and physics. It conducts clinical studies i …
  • University of Dundee-製薬・医療分野:企業M&A・提携分析
    Summary University of Dundee (Dundee) is an educational research university that offers a range of undergraduate, postgraduate, postgraduate research degree, distant learning and English language programs. The university offers a wide range of academic and research courses in various disciplines suc …
  • Shell Canada Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary Shell Canada Ltd (Shell Canada) a subsidiary of Royal Dutch Shell plc is an integrated oil and gas company that offers upstream and downstream services. The company's upstream services include markets and trades natural gas and power and exploration and extraction of natural gas. Its downstr …
  • Al Rajhi Banking & Investment Corporation (1120):企業の財務・戦略的SWOT分析
    Al Rajhi Banking & Investment Corporation (1120) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key s …
  • Encore Capital Group Inc:企業のM&A・事業提携・投資動向
    Encore Capital Group Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Encore Capital Group Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisiti …
  • Strongbridge Biopharma plc (SBBP):製薬・医療:M&Aディール及び事業提携情報
    Summary Strongbridge Biopharma Plc (Strongbridge Biopharma), formerly Cortendo Plc is a commercial-stage biopharmaceutical company that develops and commercializes therapies for rare diseases. The company’s marketed product KEVEYIS (dichlorphenamide) is indicated for the treatment of hypokalemic, hy …
  • Tan Chong Motor Holdings Berhad (TCHONG):企業の財務・戦略的SWOT分析
    Tan Chong Motor Holdings Berhad (TCHONG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • The Second Cup Ltd.:企業の戦略・SWOT・財務分析
    The Second Cup Ltd. - Strategy, SWOT and Corporate Finance Report Summary The Second Cup Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Expro Holdings UK 2 Limited:企業の戦略的SWOT分析
    Expro Holdings UK 2 Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Erytech Pharma SA (ERYP):製薬・医療:M&Aディール及び事業提携情報
    Summary Erytech Pharma SA (Erytech) is a clinical-stage biopharmaceutical company that provides development of therapies for rare forms of cancer and orphan diseases. The company develops pipeline of product candidates through its proprietary ERYCAPS platform. It offers product candidates which are …
  • Selecta Biosciences Inc (SELB)-製薬・医療分野:企業M&A・提携分析
    Summary Selecta Biosciences Inc (Selecta Biosciences) is a clinical-stage biopharmaceutical company which develops immunotherapies and vaccines to prevent and treat disease. The company’s pipeline products include SEL-212, SELA-070, SEL-701, LMB-100 and others. Its synthetic vaccine particle (SVP) t …
  • CDW Corporation:企業の戦略・SWOT・財務情報
    CDW Corporation - Strategy, SWOT and Corporate Finance Report Summary CDW Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Falck Renewables S.p.A. (FKR)-エネルギー分野:企業M&A・提携分析
    Summary Falck Renewables S.p.A. (Falck Renewables), formerly Actelios S.p.A., develops, designs, constructs and manages energy production plants. It operates as a subsidiary of Falck S.p.A. The company produces clean energy from various renewable sources including wind energy, solar energy, biomass …
  • Iroko Pharmaceuticals LLC-製薬・医療分野:企業M&A・提携分析
    Summary Iroko Pharmaceuticals LLC (Iroko) is a specialty pharmaceutical company that develops and commercializes pharmaceutical products. The company’s products comprise low dose Nonsteroidal anti-inflammatory drugs such as meloxicam, indomethacin, and diclofenac that are in various stages of noncli …
  • BOE Technology Group Co Ltd:戦略・SWOT・企業財務分析
    BOE Technology Group Co Ltd - Strategy, SWOT and Corporate Finance Report Summary BOE Technology Group Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Ames Construction Inc:企業の戦略的SWOT分析
    Ames Construction Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Caixa Economica Federal:企業の戦略・SWOT・財務分析
    Caixa Economica Federal - Strategy, SWOT and Corporate Finance Report Summary Caixa Economica Federal - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Inovise Medical, Inc.:企業の戦略的SWOT分析
    Inovise Medical, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Pharmaron Beijing Co Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Pharmaron Beijing Co Ltd (Pharmaron) is a life science service company that provides drug research and development services in the areas of chemistry, biology, pharmacology, DMPK, toxicology, and chemical development. The company's service offerings include synthetic, medicinal and analytica …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆